Pioneering Solutions for Parkinson's Disease
Diagnostics and Therapeutics
Rapid, Accurate qPCR Blood-based Diagnostic Test
ATED Therapeutics, with Hebrew University in Jerusalem, has developed a new, rapid, simple, transfer RNA fragment (tRF), non-invasive blood based diagnostic test for Parkinson’s Disease. In addition to detecting Parkinson’s Disease in its earliest stages, the test also is:
the first biomarker to give a quantitative measurement of the effectiveness of deep brain stimulation.
may be a biomarker for the likelihood of Parkinson’s developing in concussed athletes.
10M+ Cases Worldwide
|
11.3% CAGR,
|
90,000 New cases per year in US
-------------------
10M+ Cases Worldwide | 11.3% CAGR, | 90,000 New cases per year in US -------------------
Collaborations
Disclaimer: This content is not intended to be medical or clinical advice and visitors to this website should not take the content as medical advice. ATED Therapeutics does not aim to give such medical or clinical advice, and each decision should be made by the visitor and their physicians.